Drug Trial Radar · NCT07510100
Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
17
Planned (sponsor's estimate)
Start
May 10, 2026
Primary completion
Aug 31, 2029
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Nanjing IASO Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)Drug
Eque-cel consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that contains a unique CAR structure with a fully human single-chain variable fragment (scFv).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety endpoint (Part 1)- Adverse Event(AEs)Time frame: up to 2 years from Eque-cel infusion
- Safety endpoint (Part 1)-CRSTime frame: up to 2 years from Eque-cel infusion
- Safety endpoint (Part 1)-ICANSTime frame: up to 2 years from Eque-cel infusion
- Efficacy endpoint (Part 2): Independent Review Committee (IRC)-assessed ORRTime frame: up to 2 years from Eque-cel infusion
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Institute of Science Tokyo Hospital
Bunkyo-ku, Tokyo, Japan
Japanese Red Cross Medical Center
Shibuya-ku, Tokyo, Japan
Nihon University Itabashi Hospital
tabashi City, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.